NCT06701838View on ClinicalTrials.gov

Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection

Not yet recruitingOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

July 5, 2026

Study Completion Date

July 5, 2026

Conditions
Cushing's DiseaseHypercortisolismPituitary AdenomaPituitary ACTH Secreting Adenoma
Interventions
DIAGNOSTIC_TEST

11C-Methionine PET/CT

After a 3-month period of eucortisolaemia, patients will undergo a second MRI of the pituitary gland and 11C-methionine PET/CT scan with SUVmax ratio analysis of the presumed corticotroph pituitary adenoma.

All Listed Sponsors
collaborator

University of Cambridge

OTHER

lead

Imperial College London

OTHER

NCT06701838 - Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection | Biotech Hunter | Biotech Hunter